Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | PDE5A | O76074 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6441707 | 1.00 | KMT2A (1.00) | KMT2APDE5AALDH1A1CYP2D6PKM | |
| Hydrochloric Acid SCHEMBL6442412 | 0.99 | KMT2A (0.98) | KMT2APDE5AALDH1A1CYP2D6PKM | |
| Hydrochloric Acid SCHEMBL6386723 | 0.99 | KMT2A (0.98) | KMT2APDE5AALDH1A1CYP2D6PKM | |
| SCHEMBL6441696 | 0.99 | KMT2A (0.98) | KMT2APDE5AALDH1A1CYP2D6PKM | |
| Hydrochloric Acid SCHEMBL7388188 | 0.96 | KMT2A (0.92) | KMT2APDE5AALDH1A1CYP2D6PKM | |
| SCHEMBL7004598 | 0.94 | KMT2A (0.88) | KMT2APDE5AALDH1A1CYP2D6PKM | |
| SCHEMBL6444417 | 0.91 | KMT2A (0.83) | KMT2APDE5AALDH1A1CYP2D6PKM | |
| SCHEMBL6200528 | 0.91 | KMT2A (0.83) | KMT2APDE5AALDH1A1CYP2D6PKM | |
| SCHEMBL13500479 | 0.89 | KMT2A (0.81) | KMT2APDE5AALDH1A1GAAKDM4E | |
| Hydrochloric Acid SCHEMBL6446632 | 0.89 | KMT2A (0.80) | KMT2APDE5AALDH1A1CYP2D6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | claimed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | claimed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC | 2011-09-01 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PFIZER INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1440709-B1 | Combinations comprising cGMP PDE5 inhibitors. | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-7176311-B2 | Process for preparing pharmaceutically active compounds | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1176142-A1 | Process for the preparation of pyrazoles | PFIZER INC. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2001098303-A1 | NOVEL PROCESS FOR THE PREPARATION OF PYRAZOLOPYRIMIDINONES | PFIZER LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2001027101-A2 | ANHYDROUS SALT | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027113-A2 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2001-04-19 | — | — | WO | disclosed |
| EP-1092720-A2 | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | Pfizer Limited (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | KMT2A 4533/4885PDE5A 1/4885ALDH1A1 254/4885 |
| US-20100035891-A1 | Pharmaceutically Active Compounds | PDE5A, PDE3A, PDE3B | KMT2A 4553/4885PDE5A 1/4885ALDH1A1 758/4885 |
| US-20090264413-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | KMT2A 3472/4885PDE5A 4/4885ALDH1A1 848/4885 |
| US-20110212972-A1 | Compositions and Methods for Treating Female Sexual Dysfunction | PDE3A, PDE3B, PDE2A | KMT2A 3472/4885PDE5A 4/4885ALDH1A1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.